| Bortezomib-Induced Congestive Cardiac Failure in a Patient with Multiple Myeloma. | |
| | |
MedLine Citation:
|
PMID: 21952908 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Bortezomib therapy is known to be associated with neurological side effects and thrombocytopenia. Its cardiac side effects are however not well known. The patient, a 70-year-old woman, with a previous history of myocardial infarction and subsequent coronary stenting, was detected to have multiple myeloma stage IIIa. She was started on Inj. Bortezomib (1.3 mg/m(2)) and Tab. Dexamethasone 40 mg on a weekly basis. She showed good response to therapy. Three days after administration of the 22nd dose of bortezomib, she presented to the hospital with congestive cardiac failure. Echocardiography revealed a drop in the left ventricular ejection fraction from pretreatment levels of 45-50 to 25%. Patient was treated medically for left ventricular failure secondary to a suspected ischemic etiology. Coronary angiography revealed non-critical coronary artery disease with patent right coronary artery and left circumflex stents. The N-terminal pro-brain natriuretic peptide (NT-proBNP) levels that were initially raised 4,030 pg/ml (<125 pg/ml) declined to 2,280 pg/ml a week later and subsequently normalized over the next 2 weeks. The patient responded well to treatment and was then discharged. The left ventricular ejection normalized over the next 3 months. Cardiac side effects of bortezomib are not well reported. Elderly patients and those with preexisting cardiac conditions could be at increased cardiovascular risk. Since this risk increases once a cumulative dose of 20 mg/m(2) has been administered, patients need to be monitored more intensively once this threshold has been attained. Increased awareness of these cardiac side effects is necessary for patients' safety. |
| | |
Authors:
|
Ajay Gupta; Anvita Pandey; Sumit Sethi |
Related Documents
:
|
21806528 - Management and outcomes of patients with acute coronary syndromes in australia and new ... 15145098 - Does beta-blocker therapy improve clinical outcomes of acute myocardial infarction afte... 8774388 - Treatment of heart failure. 22578518 - Changes in left ventricular longitudinal strain with anthracycline chemotherapy in adol... 17320988 - Cardiomyocyte necrosis: alternative mechanisms, effective interventions. 6829788 - Pericardial superfusion to measure cardiac interstitial adenosine concentration. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-9-28 |
Journal Detail:
|
Title: Cardiovascular toxicology Volume: - ISSN: 1559-0259 ISO Abbreviation: - Publication Date: 2011 Sep |
Date Detail:
|
Created Date: 2011-9-28 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101135818 Medline TA: Cardiovasc Toxicol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Max Cancer Center, Saket, P-41, South Extension-2, New Delhi, India, ajayajaygupta2002@rediffmail.com. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Predictors of survival among older adults with ependymoma.
Next Document: Enantioselective organocatalytic asymmetric allylic alkylation. Bis(phenylsulfonyl)methane addition ...